tert-butyl (1-hydroxy-3-(4-methoxyphenyl)propan-2-yl)carbamate

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: tert-butyl (1-hydroxy-3-(4-methoxyphenyl)propan-2-yl)carbamate
• 英文别名: tert-butyl N-[1-hydroxy-3-(4-methoxyphenyl)propan-2-yl]carbamate
• 化学式: C₁₅H₂₃NO₄
• 分子量: 281.352
• InChiKey: PDULSURPMKMHCI-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.2
• 重原子数：
  20
• 可旋转键数：
  7
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.53
• 拓扑面积：
  67.8
• 氢给体数：
  2
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  tert-butyl (1-hydroxy-3-(4-methoxyphenyl)propan-2-yl)carbamate 在 水 、 三乙胺 、 sodium hydroxide 作用下， 以 乙醇 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 23.5h， 生成 N-tert-butyloxycarbonyl-(O-methyl)-L-β-homotyrosine
  参考文献：
  名称：

  [EN] UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF
  [FR] DÉRIVÉ D'URÉE OU SEL PHARMACOLOGIQUEMENT ACCEPTABLE DE CE DERNIER

  摘要：

  本发明提供了一种尿素化合物或其药理学上可接受的盐，具有类似甲酰肽受体1（以下简称为FPRL1）的激动剂作用，含有该尿素化合物或其药理学上可接受的盐的药物组合物，以及其药用。已发现下述一般式（I）所代表的尿素衍生物或其药理学上可接受的盐具有优越的FPRL1激动剂作用。化合物（I）或其药理学上可接受的盐对于治疗、预防或抑制炎症性疾病、慢性气道疾病、癌症、败血症、过敏症状、HIV逆转录病毒感染、循环障碍、神经炎症、神经障碍、疼痛、朊病、淀粉样变性、免疫障碍等方面非常有用。

  公开号：

  WO2016189877A1
• 作为产物：
  描述：

  DL-酪氨酸 在 锂硼氢 、 碳酸氢钠 、 potassium carbonate 作用下， 以 四氢呋喃 、 乙醇 、 N,N-二甲基甲酰胺 为溶剂， 反应 72.0h， 生成 tert-butyl (1-hydroxy-3-(4-methoxyphenyl)propan-2-yl)carbamate
  参考文献：
  名称：

  Synthesis of l-epi-Capreomycidine Derivatives via C–H Amination

  摘要：

  The L-epi-capreomycidine (Cpm) derivatives were efficiently and stereoselectively synthesized via nitrene C-H insertion starling from a readily available D-Tyr. Design of a substrate that takes into account hydrogen bonding is a critical feature in order to achieve high selectivity. Our synthetic strategy could be a new access to epi-Cpm and its derivatives, which are found in several biologically active natural products.

  DOI：

  10.1021/ol201527k

文献信息

• Thienopyrimidine inhibitors of atypical protein kinase C
  申请人：Cancer Research Technology Limited

  公开号：US10183950B2

  公开（公告）日：2019-01-22

  The present application provides a compound of formula (I) or a salt thereof, wherein R1, R2, R3, R4, R5, R6, A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have aPKC inhibitory activity, and may be used to treat proliferative disorders.

  本申请提供了一种式 (I) 的化合物 或其盐，其中 R1、R2、R3、R4、R5、R6、A、G、M、Q 和 X 如本文所定义。式（I）化合物及其盐具有 PKC 抑制活性，可用于治疗增殖性疾病。
• Discovery of BMS-986235/LAR-1219: A Potent Formyl Peptide Receptor 2 (FPR2) Selective Agonist for the Prevention of Heart Failure
  作者：Yoshikazu Asahina、Nicholas R. Wurtz、Kazuto Arakawa、Nancy Carson、Kiyoshi Fujii、Kazunori Fukuchi、Ricardo Garcia、Mei-Yin Hsu、Junichi Ishiyama、Bruce Ito、Ellen Kick、John Lupisella、Shingo Matsushima、Kohei Ohata、Jacek Ostrowski、Yoshifumi Saito、Kosuke Tsuda、Francisco Villarreal、Hitomi Yamada、Toshikazu Yamaoka、Ruth Wexler、David Gordon、Yasushi Kohno

  DOI：10.1021/acs.jmedchem.9b02101

  日期：2020.9.10

  Formyl peptide receptor 2 (FPR2) agonists can stimulate resolution of inflammation and may have utility for treatment of diseases caused by chronic inflammation, including heart failure. We report the discovery of a potent and selective FPR2 agonist and its evaluation in a mouse heart failure model. A simple linear urea with moderate agonist activity served as the starting point for optimization. Introduction of a pyrrolidinone core accessed a rigid conformation that produced potent FPR2 and FPR1 agonists. Optimization of lactam substituents led to the discovery of the FPR2 selective agonist 13c, BMS-986235/LAR-1219. In cellular assays 13c inhibited neutrophil chemotaxis and stimulated macrophage phagocytosis, key end points to promote resolution of inflammation. Cardiac structure and functional improvements were observed in a mouse heart failure model following treatment with BMS-986235/LAR-1219.
• THIENOPYRIMIDINE INHIBITORS OF ATYPICAL PROTEIN KINASE C
  申请人：Cancer Research Technology Limited

  公开号：US20190106433A1

  公开（公告）日：2019-04-11

  The present application provides a compound of formula (I) or a salt thereof, wherein R 1 , R 2 , R 3 , R 4 , R 5 , R 6 , A, G, M, Q and X are as defined herein. A compound of formula (I) and its salts have a PKC inhibitory activity, and may be used to treat proliferative disorders.
• [EN] UREA DERIVATIVE OR PHARMACOLOGICALLY ACCEPTABLE SALT THEREOF<br/>[FR] DÉRIVÉ D'URÉE OU SEL PHARMACOLOGIQUEMENT ACCEPTABLE DE CE DERNIER
  申请人：KYORIN SEIYAKU KK

  公开号：WO2016189877A1

  公开（公告）日：2016-12-01

  The present invention provides a urea compound or a pharmacologically acceptable salt thereof that has a formyl peptide receptor like 1 (hereinafter may be abbreviated as FPRL1) agonist effect, a pharmaceutical composition containing the urea compound or the pharmacologically acceptable salt thereof, and a pharmaceutical use thereof. It has been found that a urea derivative represented by the general formula (I) below or a pharmacologically acceptable salt thereof has a superior FPRL1 agonist effect. Compound (I) or a pharmacologically acceptable salt thereof is highly useful for treatment, prevention, or suppression of inflammatory diseases, chronic airway diseases, cancers, septicemia, allergic symptoms, HIV retrovirus infection, circulatory disorders, neuroinflammation, nervous disorders, pains, prion diseases, amyloidosis, immune disorders and the like.

  本发明提供了一种尿素化合物或其药理学上可接受的盐，具有类似甲酰肽受体1（以下简称为FPRL1）的激动剂作用，含有该尿素化合物或其药理学上可接受的盐的药物组合物，以及其药用。已发现下述一般式（I）所代表的尿素衍生物或其药理学上可接受的盐具有优越的FPRL1激动剂作用。化合物（I）或其药理学上可接受的盐对于治疗、预防或抑制炎症性疾病、慢性气道疾病、癌症、败血症、过敏症状、HIV逆转录病毒感染、循环障碍、神经炎症、神经障碍、疼痛、朊病、淀粉样变性、免疫障碍等方面非常有用。
• Synthesis of <scp>l</scp>-<i>epi</i>-Capreomycidine Derivatives via C–H Amination
  作者：Tetsuya Tanino、Satoshi Ichikawa、Akira Matsuda

  DOI：10.1021/ol201527k

  日期：2011.8.5

  The L-epi-capreomycidine (Cpm) derivatives were efficiently and stereoselectively synthesized via nitrene C-H insertion starling from a readily available D-Tyr. Design of a substrate that takes into account hydrogen bonding is a critical feature in order to achieve high selectivity. Our synthetic strategy could be a new access to epi-Cpm and its derivatives, which are found in several biologically active natural products.